Some of the world’s biggest drugmakers are joining forces with rivals to help produce Covid-19 vaccines, forging unusual alliances that promise to substantially increase supplies by this summer. As we write in Chapter 5, Design of Goods and Services, alliances are a good strategy “when substantial resources are required and sizable risk is present.”
Normally big pharm companies compete to sell cancer, arthritis and other drugs. The desperate need for Covid-19 vaccines, however, is turning fierce industry competitors into fast pandemic friends. Sanofi SA recently agreed to help make a vaccine from Pfizer after Sanofi’s experimental Covid-19 shot suffered a 5-month setback, freeing up a production line in Frankfurt. Novartis AG also agreed to hep Pfizer produce more doses.
The collaborations, along with the authorization of newer vaccines and fine-tuning by the vaccine makers themselves, could help significantly boost global output, reports The Wall Street Journal (Feb. 24, 2021). Early supplies have been limited, as vaccine makers needed time to increase production and overcome early hiccups and problems getting raw materials.
The production alliances are the latest example of industry rivals coming together to fight the pandemic, starting with research tie-ups. They build upon a year-long effort by the drug industry and partners to crank up capabilities to make everything from the tiny vials that hold the shots to raw ingredients that make them. But production can’t start overnight. Vaccine manufacturing is a complex process that often requires training staff, upgrading facilities and buying new equipment.
Novavax, which has a vaccine in the late stages of development, doesn’t own a manufacturing plant and has to lean on other companies to produce the shot. Baxter said one of its plants in Germany will help fill and finish Novavax’s vaccine, as did Endo in Rochester, Michigan–under pressure from the U.S. government.
Classroom discussion questions:
- What will happen to these alliances once the pandemic is under control?
- Why is it challenging to produce the new vaccines for another company?